Natus Medical Inc (BABY) 40.64 $BABY The Cooper
Post# of 273257
Posted On: 09/04/2016 7:23:56 AM
Natus Medical Inc (BABY) 40.64 $BABY
The Cooper Companies (COO) Beats Q3 Earnings, View Up
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:27AM CDT
The Cooper Companies Inc. (COO) reported adjusted earnings of $2.30 in the third quarter of 2016, beating the Zacks Consensus Estimate by 2 cents and improving 16.8% on a year-over-year basis.
BABY: 40.64 (+0.93), QDEL: 21.58 (-0.16), IDXX: 114.09 (+0.93), COO: 185.92 (+0.55)
FEI Shareholders Approve Thermo Fisher Deal (Revised)
Urmimala Biswas - Zacks Investment Research - Thu Sep 01, 4:44PM CDT
Shareholders of FEI recently approved mega $4.2 billion deal to be acquired by Thermo Fisher Scientific.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), TMO: 151.18 (+0.23), IDXX: 114.09 (+0.93)
Thermo Fisher Shareholders Approve FEI Deal, Grows in Electron Microscopy (Revised)
Urmimala Biswas - Zacks Investment Research - Thu Sep 01, 2:59PM CDT
Shareholders of Thermo Fisher recently approved its previously announced mega $4.2 billion acquisition of FEI Company.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), TMO: 151.18 (+0.23), IDXX: 114.09 (+0.93)
Becton, Dickinson Hits 52-Week High on Solid Q3, Outlook
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 10:13AM CDT
Shares of Becton, Dickinson and Company (BDX) scaled a new 52-week high of $178.79 on Jul 31, eventually closing nominally lower at $177.21.
BABY: 40.64 (+0.93), BDX: 177.32 (+0.30), MASI: 59.90 (+0.47), NUVA: 66.74 (+0.68)
Thermo Fisher Closes FEI Deal, Grows in Electron Microscopy
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 6:42AM CDT
Thermo Fisher Scientific, Inc. (TMO) recently completed its earlier announced mega $4.2 billion acquisition of FEI Company.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), TMO: 151.18 (+0.23), IDXX: 114.09 (+0.93)
Inogen Hits 52-Week High on Solid Q2 & Estimate Revision
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:01AM CDT
Share price of Inogen Inc (INGN) rallied to a new 52-week high of $59 on Aug 30, eventually closing a tad bit lower at $58.46.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), INGN: 58.11 (+0.16), NUVA: 66.74 (+0.68)
Veeva Systems (VEEV) Q2 Earnings, Revenues Top; View Up
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:57AM CDT
Veeva Systems (VEEV) reported adjusted earnings of 15 cents per share in the second-quarter fiscal 2017, a 20.9% increase on a year-over-year basis.
VEEV: 40.74 (+0.51), BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), NUVA: 66.74 (+0.68)
PetMed Remains Strong on New Order Sales; Reorder Dips
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:44AM CDT
On Aug 29, 2016, we issued an updated research report on PetMed Express (PETS). This nationwide pet pharmacy presently carries a Zacks Rank #2 (Buy).
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), PETS: 20.38 (+0.19), IDXX: 114.09 (+0.93)
Varian Medical Hits 52 week High, Oncology Prospects Bright
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:56AM CDT
Share price of Varian Medical rallied to a new 52-week high of $96.31 on Aug 29.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), VAR: 96.41 (+0.52), IDXX: 114.09 (+0.93)
INC Research Upgraded to Strong Buy on Estimate Revision
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:26AM CDT
On Aug 27, Zacks Investment Research raised INC Research Holdings Inc. (INCR) to a Zacks Rank #1 (Strong Buy).
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), ABCO: 42.22 (+0.04), INCR: 44.01 (+0.19)
Abaxis Hurt by Dismal Q1 Results & Fierce Competition
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 7:32AM CDT
Abaxis' (ABAX) first-quarter fiscal 2017 results disappointed us, with the company squarely missing the Zacks Consensus Estimate.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), ABAX: 49.50 (-0.90), IDXX: 114.09 (+0.93)
Cigna Okays 3D Mammogram: Is Hologic Poised to Gain?
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 6:55AM CDT
Hologic's (HOLX) Genius 3D mammogram is the only clinically proven test to detect cancer 15 months earlier than traditional 2D screenings.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), IDXX: 114.09 (+0.93), HOLX: 38.51 (+0.05)
5 Medical Device Stocks to Buy on Q2 Earnings
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 9:22AM CDT
We have picked five stocks on solid Zacks Rank.
ISRG: 688.37 (-1.32), BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), IDXX: 114.09 (+0.93), CRY: 16.23 (+0.39)
Edwards Lifesciences: Rallies on Strong THV Sales, View Up
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 5:05PM CDT
Geographically Edwards Lifesciences (EW) excelled in both the U.S. as well as overseas, particularly in its transcatheter heart valve (THV) product segment.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), EW: 115.85 (-0.02), IDXX: 114.09 (+0.93)
STERIS Hit by Currency Fluctuations, Customer Consolidation
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 10:27AM CDT
STERIS' (STE) first-quarter results exceeded the Zacks Consensus Estimate on bottom-line front, the top line failed to meet the same
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), STE: 71.00 (+0.89), IDXX: 114.09 (+0.93)
BioTelemetry (BEAT) Scales New 52-Week High on Solid Q2
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 8:14AM CDT
Share price of BioTelemetry rallied to a new 52-week high of $21.42 on Aug 18.
BABY: 40.64 (+0.93), BEAT: 18.82 (+0.12), CRY: 16.23 (+0.39), NUVA: 66.74 (+0.68)
Healthways: A Strong Buy on Solid Q2, Estimate Revision
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 7:54AM CDT
On Aug 16, Zacks Investment Research upgraded Healthways, Inc to a Zacks Rank #1 (Strong Buy).
BABY: 40.64 (+0.93), HWAY: 24.96 (+0.10), IDXX: 114.09 (+0.93), CRY: 16.23 (+0.39)
Masimo (MASI) Gets CE Mark for Respiration Sensor RAS-45
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 7:35AM CDT
Masimo recently announced the receipt of CE mark for RAS-45 respiration sensor for "rainbow acoustic monitoring" of respiration rate.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), CRY: 16.23 (+0.39), NUVA: 66.74 (+0.68)
Allscripts' (MDRX) Sunrise Platform Uptake on the Rise
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 8:47AM CDT
Allscripts Healthcare Solutions recently announced that its Sunrise platform has been selected by The Bahamian Ministry of Health and the Public Hospitals Authority.
BABY: 40.64 (+0.93), MDRX: 12.88 (-0.03), IDXX: 114.09 (+0.93), CRY: 16.23 (+0.39)
Teleflex Launches Advanced Percutaneous Surgical System
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 5:45AM CDT
Following the U.S. Food and Drug Administration's clearance, Teleflex Incorporated (TFX) announced the launch of its second generation Percuvance Percutaneous Surgical system.
BABY: 40.64 (+0.93), TFX: 185.59 (+1.49), IDXX: 114.09 (+0.93), CRY: 16.23 (+0.39)
The Cooper Companies (COO) Beats Q3 Earnings, View Up
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:27AM CDT
The Cooper Companies Inc. (COO) reported adjusted earnings of $2.30 in the third quarter of 2016, beating the Zacks Consensus Estimate by 2 cents and improving 16.8% on a year-over-year basis.
BABY: 40.64 (+0.93), QDEL: 21.58 (-0.16), IDXX: 114.09 (+0.93), COO: 185.92 (+0.55)
FEI Shareholders Approve Thermo Fisher Deal (Revised)
Urmimala Biswas - Zacks Investment Research - Thu Sep 01, 4:44PM CDT
Shareholders of FEI recently approved mega $4.2 billion deal to be acquired by Thermo Fisher Scientific.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), TMO: 151.18 (+0.23), IDXX: 114.09 (+0.93)
Thermo Fisher Shareholders Approve FEI Deal, Grows in Electron Microscopy (Revised)
Urmimala Biswas - Zacks Investment Research - Thu Sep 01, 2:59PM CDT
Shareholders of Thermo Fisher recently approved its previously announced mega $4.2 billion acquisition of FEI Company.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), TMO: 151.18 (+0.23), IDXX: 114.09 (+0.93)
Becton, Dickinson Hits 52-Week High on Solid Q3, Outlook
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 10:13AM CDT
Shares of Becton, Dickinson and Company (BDX) scaled a new 52-week high of $178.79 on Jul 31, eventually closing nominally lower at $177.21.
BABY: 40.64 (+0.93), BDX: 177.32 (+0.30), MASI: 59.90 (+0.47), NUVA: 66.74 (+0.68)
Thermo Fisher Closes FEI Deal, Grows in Electron Microscopy
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 6:42AM CDT
Thermo Fisher Scientific, Inc. (TMO) recently completed its earlier announced mega $4.2 billion acquisition of FEI Company.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), TMO: 151.18 (+0.23), IDXX: 114.09 (+0.93)
Inogen Hits 52-Week High on Solid Q2 & Estimate Revision
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:01AM CDT
Share price of Inogen Inc (INGN) rallied to a new 52-week high of $59 on Aug 30, eventually closing a tad bit lower at $58.46.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), INGN: 58.11 (+0.16), NUVA: 66.74 (+0.68)
Veeva Systems (VEEV) Q2 Earnings, Revenues Top; View Up
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:57AM CDT
Veeva Systems (VEEV) reported adjusted earnings of 15 cents per share in the second-quarter fiscal 2017, a 20.9% increase on a year-over-year basis.
VEEV: 40.74 (+0.51), BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), NUVA: 66.74 (+0.68)
PetMed Remains Strong on New Order Sales; Reorder Dips
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:44AM CDT
On Aug 29, 2016, we issued an updated research report on PetMed Express (PETS). This nationwide pet pharmacy presently carries a Zacks Rank #2 (Buy).
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), PETS: 20.38 (+0.19), IDXX: 114.09 (+0.93)
Varian Medical Hits 52 week High, Oncology Prospects Bright
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:56AM CDT
Share price of Varian Medical rallied to a new 52-week high of $96.31 on Aug 29.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), VAR: 96.41 (+0.52), IDXX: 114.09 (+0.93)
INC Research Upgraded to Strong Buy on Estimate Revision
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:26AM CDT
On Aug 27, Zacks Investment Research raised INC Research Holdings Inc. (INCR) to a Zacks Rank #1 (Strong Buy).
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), ABCO: 42.22 (+0.04), INCR: 44.01 (+0.19)
Abaxis Hurt by Dismal Q1 Results & Fierce Competition
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 7:32AM CDT
Abaxis' (ABAX) first-quarter fiscal 2017 results disappointed us, with the company squarely missing the Zacks Consensus Estimate.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), ABAX: 49.50 (-0.90), IDXX: 114.09 (+0.93)
Cigna Okays 3D Mammogram: Is Hologic Poised to Gain?
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 6:55AM CDT
Hologic's (HOLX) Genius 3D mammogram is the only clinically proven test to detect cancer 15 months earlier than traditional 2D screenings.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), IDXX: 114.09 (+0.93), HOLX: 38.51 (+0.05)
5 Medical Device Stocks to Buy on Q2 Earnings
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 9:22AM CDT
We have picked five stocks on solid Zacks Rank.
ISRG: 688.37 (-1.32), BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), IDXX: 114.09 (+0.93), CRY: 16.23 (+0.39)
Edwards Lifesciences: Rallies on Strong THV Sales, View Up
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 5:05PM CDT
Geographically Edwards Lifesciences (EW) excelled in both the U.S. as well as overseas, particularly in its transcatheter heart valve (THV) product segment.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), EW: 115.85 (-0.02), IDXX: 114.09 (+0.93)
STERIS Hit by Currency Fluctuations, Customer Consolidation
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 10:27AM CDT
STERIS' (STE) first-quarter results exceeded the Zacks Consensus Estimate on bottom-line front, the top line failed to meet the same
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), STE: 71.00 (+0.89), IDXX: 114.09 (+0.93)
BioTelemetry (BEAT) Scales New 52-Week High on Solid Q2
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 8:14AM CDT
Share price of BioTelemetry rallied to a new 52-week high of $21.42 on Aug 18.
BABY: 40.64 (+0.93), BEAT: 18.82 (+0.12), CRY: 16.23 (+0.39), NUVA: 66.74 (+0.68)
Healthways: A Strong Buy on Solid Q2, Estimate Revision
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 7:54AM CDT
On Aug 16, Zacks Investment Research upgraded Healthways, Inc to a Zacks Rank #1 (Strong Buy).
BABY: 40.64 (+0.93), HWAY: 24.96 (+0.10), IDXX: 114.09 (+0.93), CRY: 16.23 (+0.39)
Masimo (MASI) Gets CE Mark for Respiration Sensor RAS-45
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 7:35AM CDT
Masimo recently announced the receipt of CE mark for RAS-45 respiration sensor for "rainbow acoustic monitoring" of respiration rate.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), CRY: 16.23 (+0.39), NUVA: 66.74 (+0.68)
Allscripts' (MDRX) Sunrise Platform Uptake on the Rise
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 8:47AM CDT
Allscripts Healthcare Solutions recently announced that its Sunrise platform has been selected by The Bahamian Ministry of Health and the Public Hospitals Authority.
BABY: 40.64 (+0.93), MDRX: 12.88 (-0.03), IDXX: 114.09 (+0.93), CRY: 16.23 (+0.39)
Teleflex Launches Advanced Percutaneous Surgical System
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 5:45AM CDT
Following the U.S. Food and Drug Administration's clearance, Teleflex Incorporated (TFX) announced the launch of its second generation Percuvance Percutaneous Surgical system.
BABY: 40.64 (+0.93), TFX: 185.59 (+1.49), IDXX: 114.09 (+0.93), CRY: 16.23 (+0.39)
(0)
(0)Scroll down for more posts ▼